Gastric cancer treatment moving along!

Week's Best Articles: Oncology

And they went ahead and did it. combining Rilotumumab with standard ECX in gastric cancer in patients who are MET positive " dose de-escalation study to identify a safe dose of rilotumumab (initial dose 15 mg/kg intravenously on day 1) plus ECX (epirubicin 50 mg/m2 intravenously on day 1, cisplatin 60 mg/m2 intravenously on day 1, capecitabine 625 mg/m2 twice a day orally on days 1—21, respectively), administered every 3 weeks."  MDLINKS the NIH reported: " rilotumumab  A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Rilotumumab binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis." ================ This will mark progress in Gastric cancer next will see Ramucirumab (VEGF) combined to this same combination in the same disease... and may be we will see progress in Gastric Cancer after all